Porges sees the pros — and cons — for Biogen in Lilly’s Alzheimer’s snafu; Idera forges development pact; UK government adds more cash for R&D programs
Leerink’s Geoffrey Porges had some good news and some bad news to relate to Biogen $BIIB on Friday. The good news is that Eli …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
